Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Filings indexed 666 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-19 English
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Regulatory Filings
2026-05-14 English
S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer)
Registration Form
2026-03-19 English
10-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
Annual Report FY 2025
2026-03-19 English
8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
Regulatory Filings
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.